Summary

pailisrael1 Users

  • A singular dominant-negative PD-1 armored anti-CD19 CAR Capital t mobile or portable is safe and efficient in opposition to refractory/relapsed B cell lymphoma.
Offline Offline
Posts:
0 (0 per day)
Age:
N/A
Date Registered:
2025-07-11, 11:13:20
Local Time:
2025-07-16, 19:47:14
Last Active:
2025-07-11, 16:03:18
Signature:
The primary safety outcome was met compared with the performance goal (21.8% vs. 35%, P < 0.0001). The primary hierarchical efficacy en